Modulation of CXCL-8 expression in human melanoma cells regulates tumor growth, angiogenesis, invasion, and metastasis

Cancer Medicine

Volumn 1, Issue 3, 2012, Pages 306-317

  Wu, Sheng ^a   Singh, Seema ^b   Varney, Michelle L ^a   Kindle, Scott ^a   Singh, Rakesh K ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Angiogenesis; CXCL 8; Melanoma; Metastasis; Proliferation

Indexed keywords

INTERLEUKIN 8;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAPILLARY DENSITY; CELL DEATH; CELL MIGRATION; CELL PROLIFERATION; CLONOGENESIS; COLONY FORMATION; EXPRESSION VECTOR; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TUMOR CELL LINE; TUMOR GROWTH; TUMOR INVASION;

EID: 84897064917     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.28     Document Type: Article

References (36)

1. Rigel, D. S., J. Russak, and R. Friedman 2010. The evolution of melanoma diagnosis: 25 years beyond the ABCDs. CA Cancer J. Clin. 60:301-316.
2. Siegel, R., E. Ward, O. Brawley, and A. Jemal 2011. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J. Clin. 61:212-236.
3. Gray-Schopfer, V., C. Wellbrock, and R. Marais 2007. Melanoma biology and new targeted therapy. Nature 445:851-857.
4. Wu, S., and R. K. Singh 2011. Resistance to chemotherapy and molecularly targeted therapies: rationale for combination therapy in malignant melanoma. Curr. Mol. Med. 11:553-563.
5. Balkwill, F. 2004. Cancer and the chemokine network. Nat. Rev. Cancer 4:540-550.
6. Singh, R. K., M. Gutman, R. Radinsky, C. D. Bucana, and I. J. Fidler 1994. Expression of interleukin-8 correlates with the metastatic potential of human-melanoma cells in nude-mice. Cancer Res. 54:3242-3247.
7. Varney, M. L., A. H. Li, B. J. Dave, C. D. Bucana, S. L. Johansson, and R. K. Singh 2003. Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype. Clin. Exp. Metastasis 20:723-731.
8. Li, A. H., S. Dubey, M. L. Varney, and R. K. Singh 2002. Interleukin-8-induced proliferation, survival, and MMP production in CXCR1 and CXCR2 expressing human umbilical vein endothelial cells. Microvasc. Res. 64:476-481.
9. Varney, M. L., S. L. Johansson, and R. K. Singh 2006. Distinct expression of CXCL8 and its receptors CXCRI1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am. J. Clin. Pathol. 125:209-216.
10. Waugh, D. J. J., and C. Wilson 2008. The interleukin-8 pathway in cancer. Clin. Cancer Res. 14:6735-6741.
11. Singh, R. K., M. Gutman, R. Reich, and M. Bareli 1995. Ultraviolet-B irradiation promotes tumorigenic and metastatic properties in primary cutaneous melanoma via induction of interleukin-8. Cancer Res. 55:3669-3674.
12. Huang, S. Y., L. Mills, B. Mian, et al. 2002. Fully humanized neutralizing antibodies to interleukin-8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am. J. Pathol. 161:125-134.
13. Singh, S., A. Sadanandam, K. C. Nannuru, et al. 2009. Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis. Clin. Cancer Res. 15:2380-2386.
14. Christofakis, E. P., H. Miyazaki, D. S. Rubink, and W. A. Yeudall 2008. Roles of CXCL8 in squamous cell carcinoma proliferation and migration. Oral Oncol. 44:920-926.
15. Zhu, Y. M., S. J. Webster, D. Flower, and P. J. Woll 2004. Interleukin-8/CXCL8 is a growth factor for human lung cancer cells. Br. J. Cancer 91:1970-1976.
16. Ginestier, C., S. L. Liu, M. E. Diebel, et al. 2010. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest. 120:485-497.
17. Singh, R. K., and M. L. Varney 1998. Regulation of interleukin 8 expression in human malignant melanoma cells. Cancer Res. 58:1532-1537.
18. Singh, S., K. C. Nannuru, A. Sadanandam, M. L. Varney, and R. K. Singh 2009. CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br. J. Cancer 100:1638-1646.
19. Singh, S., A. Sadanandam, M. L. Varney, K. C. Nannuru, and R. K. Singh 2010. Small interfering RNA-mediated CXCR1 or CXCR2 knock-down inhibits melanoma tumor growth and invasion. Int. J. Cancer 126:328-336.
20. Nannuru, K. C., S. Singh, and R. K. Singh 2010. Chemokines and metastasis. Pp. 601-632 in B. Theicher and R. G. Bagley, eds. The tumor microenvironment: cancer drug discovery and development. Springer Sciences, Berlin.
21. Lazennec, G., and A. Richmond 2010. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol. Med. 16:133-144.
22. Singh, S., M. Varney, and R. K. Singh 2009. Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res. 69:411-415.
23. Murakami, T., A. R. Cardones, and S. T. Hwang 2004. Chemokine receptors and melanoma metastasis. J. Dermatol. Sci. 36:71-78.
24. Balentien, E., B. E. Mufson, R. L. Shattuck, R. Derynck, and A. Richmond 1991. Effects of Mgsa Gro-alpha on melanocyte transformation. Oncogene 6:1115-1124.
25. Haghnegahdar, H., J. G. Du, D. Z. Wang, et al. 2000. The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma. J. Leukoc. Biol. 67:53-62.
26. Owen, J. D., R. Strieter, M. Burdick, et al. 1997. Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma proteins. Int. J. Cancer 73:94-103.
27. Mrowietz, U., U. Schwenk, S. Maune, et al. 1999. The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br. J. Cancer 79:1025-1031.
28. Meier, F., B. Schittek, S. Busch, et al. 2005. The Ras/Raf/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front. Biosci. 10:2986-3001.
29. Wilson, C., C. Purcell, A. Seaton, et al. 2008. Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappa B transcription and evasion of apoptosis. J. Pharmacol. Exp. Ther. 327:746-759.
30. Li, A. H., S. Dubey, M. L. Varney, B. J. Dave, and R. K. Singh 2003. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J. Immunol. 170:3369-3376.
31. Li, A., M. L. Varney, J. Valasek, M. Godfrey, and R. K. Singh 2005. Autocrine role of interleukin-8 in induction of endothelial cell proliferation, survival, migration and MMP-2 production and angiogenesis. Angiogenesis 8:63-71.
32. Luca, M., S. Y. Huang, J. E. Gershenwald, R. K. Singh, R. Reich, and M. Bareli 1997. Expression of interleukin-8 by human melanoma cells up-regulates MMP-2 activity and increases tumor growth and metastasis. Am. J. Pathol. 151:1105-1113.
33. Inoue, K., J. W. Slaton, B. Y. Eve, et al. 2000. Interleukin 8 expression regulates tumorigenicity and metastases in androgen-independent prostate cancer. Clin. Cancer Res. 6:2104-2119.
34. Lev, D. C., M. Ruiz, L. Mills, E. C. Mcgary, J. E. Price, and M. Bar-Eli 2003. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol. Cancer Ther. 2:753-763.
35. Kunz, M., A. Hartmann, E. Flory, et al. 1999. Anoxia-induced up-regulation of interleukin-8 in human malignant melanoma - a potential mechanism for high tumor aggressiveness. Am. J. Pathol. 155:753-763.
36. Rofstad, E. K., B. Mathiesen, K. Henriksen, K. Kindem, and K. Galappathi 2005. The tumor bed effect: increased metastatic dissemination from hypoxia-induced up-regulation of metastasis-promoting gene products. Cancer Res. 65:2387-2396.